Advertisement
Advertisement
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
18.14
USDSponsored
+0.07
+0.39%
Aug 07, 15:59 UTC -4
Closed
After-Market
18.60
+0.46
+2.55%
AMRX Earnings Reports
Positive Surprise Ratio
AMRX beat 29 of 43 last estimates.
67%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$825.06M
/$0.23
Implied change from Q2 26 (Revenue/ EPS)
+3.62%
/-23.33%
Implied change from Q3 25 (Revenue/ EPS)
+5.17%
/+35.29%
Amneal Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue
On Jul 30, 2026, AMRX reported earnings of 0.30 USD per share (EPS) for Q2 26, beating the estimate of 0.22 USD, resulting in a 32.80% surprise. Revenue reached 796.20 million, compared to an expected 783.57 million, with a 1.61% difference. The market reacted with a -3.14% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of 0.23 USD, with revenue projected to reach 825.06 million USD, implying an decrease of -23.33% EPS, and increase of 3.62% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Relay Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.41
Surprise
-2.78%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Profound Medical Corp. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
$0.26
Surprise
+199.01%
OmniAb, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+59.15%
FAQ
What were Amneal Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Amneal Pharmaceuticals, Inc. Class A Common Stock reported EPS of $0.30, beating estimates by 32.8%, and revenue of $796.20M, 1.61% above expectations.
How did the market react to Amneal Pharmaceuticals, Inc. Class A Common Stock's Q2 2026 earnings?
The stock price moved down -3.14%, changed from $19.10 before the earnings release to $18.50 the day after.
When is Amneal Pharmaceuticals, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for Amneal Pharmaceuticals, Inc. Class A Common Stock's next earnings report?
Based on 6
analysts, Amneal Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of $0.23 and revenue of $825.06M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement